Low molecular weight inhibitors of Prolyl Oligopeptidase: A review of compounds patented from 2003 to 2010

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 7, 2011, Pages 1023-1044

  López, Abraham ^a,b   Tarragó, Teresa ^a   Giralt, Ernest ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimers disease; cognitive disorders; neurological disorders; Parkinsons disease; Prolyl Oligopeptidase; Prolyl Oligopeptidase inhibitors

Indexed keywords

1 [N (4 CHLOROBENZYL)SUCCINAMOYL]PROLINAL; 2 (8 DIMETHYLAMINOOCTYLTHIO) 6 ISOPROPYL 3 PYRIDYL 2 THIENYL KETONE CITRATE; 3 (2 INDANYLACETYL) 4 (1 PYRROLIDINYLCARBONYL)THIAZOLIDINE; ALKALOID DERIVATIVE; ANGIOTENSIN II; ARGIPRESSIN; BENZYLOXYCARBONYLPROLYLPROLINAL; BRADYKININ; HUMANIN; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; NEUROPEPTIDE; NEUROTENSIN; OXYTOCIN; PEPTIDE HORMONE; PEPTIDOMIMETIC AGENT; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; PROTIRELIN; S 17092; SUAM 1221; SUBSTANCE P; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD BRAIN BARRIER; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROLYSIS; MENTAL DISEASE; MOLECULAR WEIGHT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOPHORE; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW;

ALKALOIDS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; KETONES; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; PATENTS AS TOPIC; PEPTIDOMIMETICS; SERINE ENDOPEPTIDASES;

EID: 79959422016     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.577416     Document Type: Review

References (129)

1. Fulop V, Bocskei Z, Polgar L. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 1998;21(2):161-70 (Pubitemid 28348004)
2. Polgar L. Structural relationship between lipases and peptidases of the prolyl oligopeptidase family. FEBS Lett 1992;311(3):281-4
3. Szeltner Z, Rea D, Juhasz T, et al. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. J Mol Biol 2004;340(3):627-37 (Pubitemid 38798005)
4. Juhasz T, Szeltner Z, Fulop V, Polgar L. Unclosed beta-propellers display stable structures: implications for substrate access to the active site of prolyl oligopeptidase. J Mol Biol 2005;346(3):907-17 (Pubitemid 40247726)
5. Fuxreiter M, Magyar C, Juhasz T, et al. Flexibility of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. Proteins 2005;60(3):504-12 (Pubitemid 41061642)
6. Li M, Chen C, Davies DR, Chiu TK. Induced-fit Mechanism for Prolyl Endopeptidase. J Biol Chem 2010;285(28):21487-95
7. Tarrago T, Martin-Benito J, Sabido E, et al. A new side opening on prolyl oligopeptidase revealed by electron microscopy. FEBS Lett 2009;583:3344-48
8. Tarrago T, Claasen B, Kichik N, et al. A cost-effective labeling strategy for the NMR study of large proteins: selective 15N-labeling of the tryptophan side chains of prolyl oligopeptidase. ChemBioChem 2009;10:2736-9
9. Cunningham DF, O'Connor B. Proline specific peptidases. Biochim Biophys Acta 1997;1343(2):160-86 (Pubitemid 28015033)
10. Rennex D, Hemmings BA, Hofsteenge J, Stone SR. cDNA cloning of porcine brain prolyl endopeptidase and identification of the active-site seryl residue. Biochemistry 1991;30(8):2195-203
11. Yoshimoto T, Kanatani A, Shimoda T, et al. Prolyl endopeptidase from Flavobacterium meningosepticum: cloning and sequencing of the enzyme gene. J Biochem 1991;110(6):873-8
12. Chevallier S, Goeltz P, Thibault P, et al. Characterization of a prolyl endopeptidase from Flavobacterium meningosepticum. Complete sequence and localization of the active-site serine. J Biol Chem 1992;267(12):8192-9
13. Kabashima T, Fujii M, Meng Y, et al. Prolyl endopeptidase from Sphingomonas capsulata: isolation and characterization of the enzyme and nucleotide sequence of the gene. Arch Biochem Biophys 1998;358(1):141-8 (Pubitemid 28471383)
14. Ishino T, Ohtsuki S, Homma K, Natori S. cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J Biochem 1998;123(3):540-5 (Pubitemid 28143512)
15. Robinson KA, Bartley DA, Robb FT, Schreier HJ. A gene from the hyperthermophile Pyrococcus furiosus whose deduced product is homologous to members of the prolyl oligopeptidase family of proteases. Gene 1995;152(1):103-6
16. Shirasawa Y, Osawa T, Hirashima A. Molecular cloning and characterization of prolyl endopeptidase from human T cells. J Biochem 1994;115(4):724-9 (Pubitemid 24119397)
17. Vanhoof G, Goossens F, Hendriks L, et al. Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene 1994;149(2):363-6 (Pubitemid 24361932)
18. Wilk S. Prolyl endopeptidase. Life Sci 1983;33(22):2149-57 (Pubitemid 14234451)
19. Myohanen TT, Garcia-Horsman JA, Tenorio-Laranga J, Mannisto PT. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem 2009;57(9):831-48
20. Irazusta J, Larrinaga G, Gonzalez-Maeso J, et al. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int 2002;40(4):337-45 (Pubitemid 34131608)
21. Moreno-Baylach MJ, Felipo V, Mannisto PT, Garcia-Horsman JA. Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience 2008;156(3):580-5
22. Garcia-Horsman JA, Mannisto PT, Venalainen JI. On the role of prolyl oligopeptidase in health and disease. Neuropeptides 2007;41(1):1-24 (Pubitemid 46091700)
23. Reichelt KL, Hole K, Hamberger A, et al. Biologically active peptide-containing fractions in schizophrenia and childhood autism. Adv Biochem Psychopharmacol 1981;28:627-43
24. Maes M, Goossens F, Scharpe S, et al. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994;35(8):545-52 (Pubitemid 24140097)
25. Maes M, Goossens F, Scharpe S, et al. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58(3):217-25
26. Toide K, Okamiya K, Iwamoto Y, Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem 1995;65(1):234-40
27. Toide K, Iwamoto Y, Fujiwara T, Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J Pharmacol Exp Ther 1995;274(3):1370-8
28. Toide K, Shinoda M, Fujiwara T, Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol Biochem Behav 1997;56(3):427-34 (Pubitemid 27145822)
29. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003;7(4):496-504 (Pubitemid 36980841)
30. Mannisto PT, Venalainen J, Jalkanen A, Garcia-Horsman JA. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect 2007;20(5):293-305 (Pubitemid 47345221)
31. Brandt I, Scharpe S, Lambeir AM. Suggested functions for prolyloligopeptidase: a puzzling paradox. Clin Chim Acta 2007;377(1-2):50-61 (Pubitemid 44914066)
32. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004;43(5):1140-5 (Pubitemid 38579927)
33. Myohanen T, Tenorio-Laranga J, Jokinen B, et al. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol 2010. Doi: 10.1111/j.1476-5381.2010.01146.x
34. Larrinaga G, Perez I, Blanco L, et al. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept 2010;163(1-3):102-6
35. Williams RS, Eames M, Ryves WJ, et al. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J 1999;18(10):2734-45
36. Komatsu Y. GABAB receptors, monoamine receptors, and postsynaptic inositol trisphosphate-induced Ca2+ release are involved in the induction of long-term potentiation at visual cortical inhibitory synapses. J Neurosci 1996;16(20):6342-52 (Pubitemid 26337358)
37. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66(2):179-89 (Pubitemid 36776392)
38. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417(6886):292-5 (Pubitemid 34534711)
39. Schulz I, Gerhartz B, Neubauer A, et al. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002;269(23):5813-20 (Pubitemid 35425579)
40. Brandt I, De Vriendt K, Devreese B, et al. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides 2005;26(12):2536-46 (Pubitemid 41676729)
41. Di Daniel E, Glover CP, Grot E, et al. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 2009;41(3):373-82
42. Szeltner Z, Morawski M, Juhasz T, et al. GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase. Biochim Biophys Acta 2010;1804(12):2162-76
43. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997;20(2):84-91 (Pubitemid 27050703)
44. Brandt I, Gerard M, Sergeant K, et al. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 2008;29(9):1472-8
45. Yoshimoto T, Kado K, Matsubara F, et al. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J Pharmacobiodyn 1987;10(12):730-5 (Pubitemid 18034462)
46. Shinoda M, Matsuo A, Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur J Pharmacol 1996;305(1-3):31-8 (Pubitemid 26196814)
47. Peltonen I, Jalkanen AJ, Sinerva V, et al. Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin Pharmacol Toxicol 2010;106(4):280-7
48. Jalkanen AJ, Puttonen KA, Venalainen JI, et al. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin Pharmacol Toxicol 2007;100(2):132-8 (Pubitemid 46146718)
49. Schneider JS, Giardiniere M, Morain P. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys. Neuropsychopharmacology 2002;26(2):176-82 (Pubitemid 34093080)
50. Kato A, Fukunari A, Sakai Y, Nakajima T. Prevention of amyloid-like deposition by a selective prolyl endopeptidase inhibitor, Y-29794, in senescence-accelerated mouse. J Pharmacol Exp Ther 1997;283(1):328-35 (Pubitemid 27438978)
51. Toide K, Shinoda M, Miyazaki A. A novel prolyl endopeptidase inhibitor, JTP-4819-its behavioral and neurochemical properties for the treatment of Alzheimer's disease. Rev Neurosci 1998;9(1):17-29 (Pubitemid 28334037)
52. Katsube N, Sunaga K, Aishita H, et al. ONO-1603, a potential antidementia drug, delays age-induced apoptosis and suppresses overexpression of glyceraldehyde-3-phosphate dehydrogenase in cultured central nervous system neurons. J Pharmacol Exp Ther 1999;288(1):6-13 (Pubitemid 29113466)
53. Morain P, Robin JL, De Nanteuil G, et al. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study. Br J Clin Pharmacol 2000;50(4):350-9
54. Morain P, Boeijinga PH, Demazieres A, et al. Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. Neuropsychobiology 2007;55(3-4):176-83 (Pubitemid 47525238)
55. Umemura K, Kondo K, Ikeda Y, et al. Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers. J Clin Pharmacol 1999;39(5):462-70 (Pubitemid 29356466)
56. De Nanteuil G, Portevin B, Lepagnol J. Prolyl endopeptidase inhibitors: a new class of memory enhancing drugs. Drugs Future 1998;23(2):167-79 (Pubitemid 28191589)
57. Lawandi J, Gerber-Lemaire S, Juillerat-Jeanneret L, Moitessier N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem 2010;53(9):3423-38
58. Yoshimoto T, Kawahara K, Matsubara F, et al. Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J Biochem 1985;98(4):975-9 (Pubitemid 16234376)
59. Kahyaoglu A, Haghjoo K, Guo F, et al. Low barrier hydrogen bond is absent in the catalytic triads in the ground state but is present in a transition-state complex in the prolyl oligopeptidase family of serine proteases. J Biol Chem 1997;272(41):25547-54 (Pubitemid 27438864)
60. Yoshimoto T, Tsuru D, Yamamoto N, et al. Structure activity relationship of inhibitors specific for prolyl endopeptidase. Agric Biol Chem 1991;55(1):37-43
61. Tran T, Quan C, Edosada CY, et al. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sarand N-blocked-boroPro inhibitors of FAP, DPP4, and POP. Bioorg Med Chem Lett 2007;17(5):1438-42 (Pubitemid 46240826)
62. Szeltner Z, Rea D, Renner V, et al. Electrostatic environment at the active site of prolyl oligopeptidase is highly influential during substrate binding. J Biol Chem 2003;278(49):48786-93 (Pubitemid 41079521)
63. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27(2):157-62
64. Abramowitz N, Schechter I, Berger A. On the size of the active site in proteases. II. Carboxypeptidase-A. Biochem Biophys Res Commun 1967;29(6):862-7
65. Tsuru D, Yoshimoto T, Koriyama N, Furukawa S. Thiazolidine derivatives as potent inhibitors specific for prolyl endopeptidase. J Biochem 1988;104(4):580-6
66. Kanai K, Erd S, Susan E, et al. Prolyl endopeptidase inhibitors: N-acyl derivatives of L-thioproline-pyrrolidine. Bioorg Med Chem Lett 1997;7(13):1701-4
67. Arai H, Nishioka H, Niwa S, et al. Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships: in vitro inhibition of prolyl endopeptidase from canine brain. Chem Pharm Bull (Tokyo) 1993;41(9):1583-8 (Pubitemid 23326786)
68. Tanaka Y, Niwa S, Nishioka H, et al. New potent prolyl endopeptidase inhibitors: synthesis and structure-activity relationships of indan and tetralin derivatives and their analogues. J Med Chem 1994;37(13):2071-8 (Pubitemid 24233619)
69. Kanai K, Aranyi P, Bocskei Z, et al. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules. J Med Chem 2008;51(23):7514-22
70. Saito M, Hashimoto M, Kawaguchi N, et al. Synthesis and inhibitory activity of acyl-peptidyl-prolinalderivatives toward post-proline cleaving enzyme as nootropic agents. J Enzyme Inhib 1990;3(3):163-78 (Pubitemid 20080687)
71. Saito M, Hashimoto M, Kawaguchi N, et al. Synthesis and inhibitory activity of acyl-peptidyl-pyrrolidine derivatives toward post-proline cleaving enzyme; a study of subsite specificity. J Enzyme Inhib 1991;5(1):51-75
72. Li J, Wilk E, Wilk S. Inhibition of prolyl oligopeptidase by Fmoc-aminoacylpyrrolidine-2-nitriles. J Neurochem 1996;66(5):2105-12 (Pubitemid 126580078)
73. Portevin B, Benoist A, Remond G, et al. New prolyl endopeptidase inhibitors: in vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1] heptane, and perhydroindole derivatives. J Med Chem 1996;39(12):2379-91 (Pubitemid 26191128)
74. Vendeville S, Bourel L, Davioud-Charvet E, et al. Automated parallel synthesis of a tetrahydroisoquinolin-based library: potential prolyl endopeptidase inhibitors. Bioorg Med Chem Lett 1999;9(3):437-42 (Pubitemid 29084508)
75. Bakker AV, Daffeh J, Jung S, et al. Novel in vitro and in vivo inhibitors of prolyl endopeptidase. Bioorg Med Chem Lett 1991;1(11):585-90
76. Jarho EM, Venalainen JI, Huuskonen J, et al. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J Med Chem 2004;47(23):5605-7 (Pubitemid 39447255)
77. Jarho EM, Venalainen JI, Poutiainen S, et al. 2(S)-(Cycloalk-1- enecarbonyl)-1-(4- phenyl-butanoyl)pyrrolidines and 2(S)- (aroyl)-1-(4- phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. Bioorg Med Chem 2007;15(5):2024-31 (Pubitemid 46176628)
78. Wilk S, Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by n-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 1983;41(1):69-75 (Pubitemid 13064897)
79. Shishido Y, Furushiro M, Tanabe S, et al. ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats. Pharmacol Biochem Behav 1996;55(3):333-8 (Pubitemid 26414132)
80. Joyeau R, Maoulida C, Guillet C, et al. Synthesis and activity of pyrrolidinyland thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi. Eur J Med Chem 2000;35(2):257-66 (Pubitemid 30165689)
81. Tsutsumi S, Okonogi T, Shibahara S, et al. Synthesis and structure-activity relationships of peptidyl alpha-keto heterocycles as novel inhibitors of prolyl endopeptidase. J Med Chem 1994;37(21):3492-502 (Pubitemid 24334605)
82. Hoechst AG. Novel pyrrolidine-2-(1,3- dicarbonyl) derivatives, a process for their preparation, agents containing them, and their use. EP0286927 (A2 and A3); 1988
83. Merrell Pharma, Inc. Prolyl endopeptidase inhibitors. US161106; 1996
84. Wallen EA, Christiaans JA, Forsberg MM, et al. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors. J Med Chem 2002;45(20):4581-4
85. Venalainen JI, Juvonen RO, Garcia-Horsman JA, et al. Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Biochem J 2004;382(Pt 3):1003-8 (Pubitemid 39312916)
86. Venalainen JI, Garcia-Horsman JA, Forsberg MM, et al. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem Pharmacol 2006;71(5):683-92 (Pubitemid 43122001)
87. Vendeville S, Goossens F, Debreu-Fontaine MA, et al. Comparison of the inhibition of human and Trypanosoma cruzi prolyl endopeptidases. Bioorg Med Chem 2002;10(6):1719-29 (Pubitemid 34286365)
88. Bal G, Van der Veken P, Antonov D, et al. Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorg Med Chem Lett 2003;13(17):2875-8 (Pubitemid 37386240)
89. Suntory Ltd. Novel thiazolidine derivative and use thereof. JP1301671 (A); 1989
90. Zeria Pharmaceuticals Co. Ltd. Phenylalkanoylamine derivatives, process for their preparation and their uses. WO 8910918; 1989
91. Zeria Pharmaceuticals Co. Ltd. Condensed benzene derivative. US5028604 (A); 1991
92. Zeria Pharmaceuticals Co. Ltd. Thiazolidine derivative and medicine containing the same. WO1995001352; 1995
93. Ono Pharmaceutical Co. Novel prolinal derivatives. EP0268190 (A1 and B1); 1988
94. Ono Pharmaceutical Co. Thiazolidine derivatives. EP0280956 (A1 and B1); 1988
95. Ono Pharmaceutical Co. Prolinal derivatives and pharmaceutical compositions thereof. US 5262431 (A); 1993
96. Ono Pharmaceutical Co. Prolinal derivatives useful for treating amnesia. US5340832 (A) US5254550 (A); 1994
97. Katsube N, Tateishi N, Matsushita Y, et al. Anti-amnesic effect of ONO-1603, a novel prolyl endopeptidase inhibitor. Jpn J Pharmacol 1989;49:91-8
98. Yoshitomi Pharmaceutical. Benzene compound. JP3255080 (A); 1991
99. Yoshitomi Pharmaceutical; Japan Tobacco, Inc. Diarylketone compound and its medicinal use. JP7126229 (A); 1995
100. Nakajima T, Ono Y, Kato A, et al. Y-29794-a non-peptide prolyl endopeptidase inhibitor that can penetrate into the brain. Neurosci Lett 1992;141(2):156-60
101. Japan Tobacco, Inc. Yoshitomi Pharmaceutical. New proline derivative. JP5025125 (A); 1993
102. Japan Tobacco, Inc. Yoshitomi Pharmaceutical. Proline derivative. JP5186498 (A); 1993
103. Japan Tobacco, Inc. Yoshitomi Pharmaceutical. New proline derivative. JP5201970 (A); 1993
104. Japan Tobacco, Inc. Yoshitomi Pharmaceutical. Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof. WO9412474 (A1); 1994
105. ADIR et Cie New nitrogenous bicyclic derivatives, process for their preparation and the pharmaceutical compositions which contain them. FR2681864 (A1) 1993
106. Barelli H, Petit A, Hirsch E, et al. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochem Biophys Res Commun 1999;257(3):657-61 (Pubitemid 29301498)
107. Kowall NW, Beal MF, Busciglio J, et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci USA 1991;88(16):7247-51 (Pubitemid 21915127)
108. Orion Corp. Compounds having prolyl oligopeptidase inhibitory activity. WO2004060862 (A2 and A3); 2005
109. Wallen EA, Christiaans JA, Saarinen TJ, et al. Conformationally rigid N-acyl-5- alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. Bioorg Med Chem 2003;11(17):3611-19 (Pubitemid 36952259)
110. Ono Pharmaceutical Co. Novel prolinal derivative, production thereof and antiamnesia containing said derivative. JP1156957 (A); 1989
111. Pfizer. Aromatic pyrrolidine and thiazolidine amides. WO9118891(A1); 1991
112. Orion Corp. Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use. WO03004468 (A1); 2003
113. Wallen EA, Christiaans JA, Jarho EM, et al. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides. J Med Chem 2003;46(21):4543-51 (Pubitemid 37238755)
114. Jarho EM, Wallen EA, Christiaans JA, et al. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions. J Med Chem 2005;48(15):4772-82 (Pubitemid 41033120)
115. Probiodrug AG. Novel compounds for the treatment of neurological disorders. WO2006058720 (A2 and A3); 2006
116. Probiodrug AG. Novel compounds. WO2009007415 (A2 and A3); 2009
117. Probiodrug AG. Inhibitors of prolyl endopeptidase. WO2006120104 (A1); 2006
118. Universitat de Barcelona; Giralt E; Tarrago T. Therapeutic agent for treatment of bipolar affective disorder in mammals. WO2008077978 (A1); 2008
119. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008;13(19-20):894-901
120. Tarrago T, Frutos S, Rodriguez-Mias RA, Giralt E. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity. Chembiochem 2006;7(5):827-33 (Pubitemid 43764193)
121. Kondo Y, Kondo F, Asanuma M, et al. Protective effect of oren-gedoku-to against induction of neuronal death by transient cerebral ischemia in the C57BL/6 mouse. Neurochem Res 2000;25(2):205-9 (Pubitemid 30210085)
122. Xu J, Murakami Y, Matsumoto K, et al. Protective effect of Oren-gedoku-to (Huang-Lian-Jie-Du-Tang) against impairment of learning and memory induced by transient cerebral ischemia in mice. J Ethnopharmacol 2000;73(3):405-13
123. Tarrago T, Kichik N, Segui J, Giralt E. The natural product berberine is a human prolyl oligopeptidase inhibitor. ChemMedChem 2007;2(3):354-9
124. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92(2):173-6
125. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10(12):1344-51 (Pubitemid 40022716)
126. Wang X, Wang R, Xing D, et al. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 2005;77(24):3058-67 (Pubitemid 41423743)
127. Wang X, Xing D, Wang W, et al. The uptake and transport behavior of berberine in Coptidis Rhizoma extract through rat primary cultured cortical neurons. Neurosci Lett 2005;379(2):132-7
128. Tarrago T, Masdeu C, Gomez E, et al. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors. ChemMedChem 2008;3:1558-65
129. Tarrago T, Kichik N, Claasen B, et al. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem 2008;16:7516-24